OKYO Pharma Ltd., an ophthalmology-focused biopharmaceutical company, has announced the receipt of $1.9 million in non-dilutive funding to advance the clinical development of urcosimod, its lead drug candidate for the treatment of Neuropathic Corneal Pain (NCP). This funding will be used to support ongoing research and development activities, specifically targeting the acceleration of urcosimod's clinical milestones and regulatory pathway. As of now, there are no FDA-approved therapies for NCP, a condition known for its chronic and severe nerve-related pain. The infusion of capital allows OKYO Pharma to continue its development strategy without affecting existing shareholder equity. No specific results from clinical studies or trials have been presented at this time.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。